DUPIXENT is an injectable medicine that is administered by subcutaneous injection and is intended for use under the guidance of a healthcare provider. Patients may self‑inject DUPIXENT, or a caregiver may administer DUPIXENT, after training has been provided by a healthcare provider on proper subcutaneous injection technique. It is important to provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use and full Prescribing Information. Patients and/or caregivers should read the Instructions for Use–either 200 mg or 300 mg—prior to injecting.1
DUPIXENT is a clear to slightly opalescent, colorless to
pale yellow solution available as:
DUPIXENT is available in cartons containing 2pre‑filled syringes with needle shields. Syringes can deliver 300 mg/2 mL or 200 mg/1.4 mL.
Advise patients and/or caregivers to read the FDA‑approved patient labeling (Patient Information and Instructions for Use ‑ 200 mg or Instructions for Use ‑ 300 mg) before the patient starts using DUPIXENT and each time the prescription is renewed as there may be new information they need to know.
Pregnancy Registry: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. Encourage participation in the registry.
Administration Instructions: Provide proper training to patients and/or caregivers on proper subcutaneous injection technique, including aseptic technique, and the preparation and administration of DUPIXENT prior to use.
Advise patients to follow sharps disposal recommendations.
Hypersensitivity:Advise patients to discontinue DUPIXENT and to seek immediate medical attention if they experience any symptoms of systemic hypersensitivity reactions.
Conjunctivitis and Keratitis:Advise patients to consult their healthcare provider if new onset or worsening eye symptoms develop.
Reduction in Corticosteroid Dosage: Inform patients to not discontinue systemic or inhaled corticosteroids except under the direct supervision of a physician. Inform patients that reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Comorbid Asthma:Advise patients with comorbid asthma not to adjust or stop their asthma treatment without talking to their physicians.
EASI, Eczema Area and Surface Index; IGA, Investigator’s Global Assessment; NRS, numerical rating scale; Q2W, once every 2 weeks; TCS, topical corticosteroids.